Black Diamond Therapeutics/$BDTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Black Diamond Therapeutics
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
- Ticker
- $BDTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 21
- Headquarters
- Cambridge, United States
BDTX Metrics
BasicAdvanced
$121m
-
-$0.74
-
-
Price and volume
Market cap
$121m
52-week high
$4.94
52-week low
$1.60
Average daily volume
970k
Financial strength
Current ratio
7.284
Quick ratio
6.975
Long term debt to equity
13.628
Total debt to equity
17.66
Profitability
EBITDA (TTM)
-44.349
Management effectiveness
Return on assets (TTM)
-19.11%
Return on equity (TTM)
-37.21%
Valuation
Price to book
1.26
Price to tangible book (TTM)
1.26
Price to free cash flow (TTM)
-3.655
Free cash flow yield (TTM)
-27.36%
Free cash flow per share (TTM)
-0.575
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-401.88%
3-year earnings per share growth (CAGR)
-31.05%
What the Analysts think about BDTX
Analyst ratings (Buy, Hold, Sell) for Black Diamond Therapeutics stock.
BDTX Financial Performance
Revenues and expenses
BDTX Earnings Performance
Company profitability
BDTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.